A new drug (UBX-303061) for B-cell cancers that came back or didn't respond
Part of Blood & lymphatic, Cancer clinical trials.
A trial testing an experimental drug (UBX-303061) for people with certain B-cell blood cancers (like CLL, DLBCL, or MCL) that have returned or not responded to at least two other treatments. The goal is to see if the drug is safe and works when other options are no longer available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your cancer (a type like CLL, DLBCL, FL, MCL, WM, or MZL) must have come back or not responded after at least two prior treatments.
- You must have tumors that can be measured or seen on scans.
- You need to have good enough organ function (liver, kidneys, bone marrow) for the study.
- You must not have had certain cancer treatments too recently, like chemotherapy in the last 3 weeks or a stem cell transplant in the last 100 days.
- You must not have had CAR-T therapy in the last 100 days or a BTK degrader drug before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ZZSW-01 for people with certain B-cell blood cancers (like lymphoma or leukemia) that have come back or haven't gotten better after other treatments. It aims to see if the drug is safe and works against these cancers.
This Phase 1 trial tests AC676, a study medicine, for adults with certain B-cell blood cancers that have come back or did not respond to prior treatment. It may help people who have tried standard therapies and need new options.
This Phase 1 study tests BXCL701 in adults whose acute myeloid leukemia (AML) or high-blast myelodysplastic syndrome (MDS-EB-2) has come back or not responded to prior treatment. The goal is to find a safe dose and see how the treatment affects cancer cells.
This trial is testing a new drug, MDX2003, for people with certain types of lymphoma that have come back after at least two prior treatments. It aims to see how safe the drug is and if it can shrink tumors.
This Phase 1 trial tests the safety and early effectiveness of NX-2127 in adults with relapsed or refractory B-cell cancers. If you qualify, you may receive a new targeted treatment because your cancer has returned or not responded to prior therapies.
This trial tests a new drug, lonitoclax, in people with certain B-cell blood cancers that have come back or not responded to earlier treatments. It aims to see if the drug can help control the disease.
Hear when a new Relapsed/Refractory B-cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.